C
Cigna Corporation
CI · Healthcare
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 10, 2026
The Toll Booth That Washington Is Actively Repricing
Most investors are debating whether Cigna is cheap on a multiple basis — the real question is whether the fee-based PBM model management is voluntarily adopting actually earns equivalent economics, or whether the rebate-free transition is the FTC extracting margin concessions that look like strategic choice but are actually capitulation.
Flowly Score
Apr 16 Close
+16%$276.37
Fair Value
$320.00
46
Below Averageat $276.37
Business Strength5/10
Evernorth is a genuine oligopoly toll road, but the political assault on its rebate economics is not a tail risk — it has already produced an FTC settlement and a forced model transition. The moat exists, but its dimensions are actively being redrawn by regulators, not competitors.
Financial Resilience6/10
The historical pattern of operating cash flow running well ahead of net income is a mark of real cash quality, but a single quarter showing a third of cash flow evaporate alongside rising debt and a falling cash balance is a yellow flag worth watching — the transition to fee-based PBM could make that pattern structural rather than episodic.
Growth & Trajectory4/10
Revenue growth is real but dominated by pharmacy pass-throughs that carry near-zero margin; the earnings trajectory has been manufactured through buybacks and below-the-line items rather than expanding operating profit; and guiding to flat medical customers in 2026 reveals a business in transition, not momentum. The rebate-free pivot is the right long-term move, but the near-term earnings path through that transition is genuinely opaque.
Valuation7/10at $269.66
Trading at less than half its own five-year average earnings multiple for a business that still generates substantial normalized cash flow looks like mispriced political risk, not fundamental impairment — but that gap only closes if the fee-based model transition preserves the margin profile management promises. The discount is wide enough to price in meaningful disappointment and still offer adequate returns.
Risk3/10
The FTC settlement landing and the rebate-free model announced in the same breath is either the clearing event that resolves years of regulatory overhang, or the first structural concession that proves the original economics were extractive and cannot be replicated in a transparent fee regime — that binary is uncomfortably wide for a business this concentrated in a single country, a single model, and a single regulatory regime.
The investment case rests on a genuine tension: Evernorth is one of three scaled pharmacy benefit operations in the country, a position that took decades and billions in acquisitions to build, and the stock reflects years of regulatory discount that has compressed the multiple far below what a comparable scale intermediary in any other industry would command. The FTC settlement, framed by management as validation of decisions already made, could prove to be precisely that — a clearinghouse event that removes the single largest source of uncertainty and allows the multiple to normalize while a relentless share reduction program compounds the per-share mathematics. The cash generation underlying the reported earnings has historically been excellent, and a business earning an earnings yield in the high single digits that still compounds its per-share metrics at mid-single digits is not obviously overpriced. But the trajectory is where the thesis gets uncomfortable. Cigna is simultaneously executing the most consequential operational transformation in its history — abandoning the rebate architecture that Express Scripts was built on — while guiding to flat customer counts, absorbing a massive FTC settlement, and asking investors to trust that fee-based economics will land at equivalent profitability. These are not the conditions under which management teams typically outperform guidance. Specialty pharmacy and biosimilar adoption are genuine growth vectors, and the GLP-1 volume flowing through the pipes is real, but volume without the rebate spread is a fundamentally different business than what investors bought when they priced in the historical earnings power. The single biggest risk is binary and structural: if the rebate-free model, once fully implemented, earns materially lower margins than the system it replaces, Cigna has voluntarily dismantled the engine that justified the Express Scripts premium. That is not a cyclical risk to wait out or a competitive threat to respond to — it is a permanent rerating of what the core franchise earns, executed by management under regulatory compulsion, with no obvious path to reversal.